Spyre Therapeutics
Biotechnology, Health Care, Therapeutics · 31 employees
Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.
Funding history
- Funding Round — $275.0M — Oct 2025
- Funding Round — $180.0M — Dec 2023
Recent signals
- Jan 17, 2026: Spyre Therapeutics Appoints Kate Tansey Chevlen as Chief Commercial Officer
- Oct 14, 2025: Raised $275.0M
- Oct 13, 2025: SEC 8-K (1.01): On October 13, 2025, Spyre Therapeutics, Inc. entered into a Material Definitive Underwriting Agreement with Jefferies LLC, TD Securities (USA) LLC, Leerink Partners LLC, and Stifel, Nicolaus & Company, Incorporated. The agreement concerned the offer and sale of 14,864,865 shares of the Company's common stock at a public offering price of $18.50 per share. Additionally, the Company granted the underwriters a 30-day option to purchase up to an additional 2,229,729 shares of common stock on the same terms, which was fully exercised on October 14, 2025. The Offering closed on October 15, 2025, generating gross proceeds of approximately $275.0 million, marking a significant capital raise for the Company, aimed at advancing its strategic initiatives and strengthening its balance sheet.
- Mar 01, 2024: Spyre Therapeutics Appoints Cameron Turtle DPhil as Chief Executive Officer
- Dec 27, 2023: Raised $180.0M
See plans & pricing → Track Spyre Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.